Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients [3]

Nephrology Dialysis Transplantation

Volumn 19, Issue 8, 2004, Pages 2156-

  Nitta, Kosaku ^a   Akiba, Takashi ^a   Nihei, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM; CHOLESTEROL; COLESTILAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; TRIACYLGLYCEROL;

AORTA DISEASE; ATTENUATION; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HEMODIALYSIS PATIENT; HUMAN; LETTER; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4344694355     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh338     Document Type: Letter

References (4)

1. Reslerova M, Moe SM. Vascular calcification in dialysis patients: pathogenesis and consequences. Am J Kidney Dis 41 [3 Suppl 1]: S96-99
2. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972-1978
3. Nitta K, Akiba T, Uchida K et al. The progression of vascular calcification and serum levels of osteoprotegerin in patients on chronic hemodialysis. Am J Kidney Dis 2003; 42: 303-309
4. Date T, Shigematsu T, Kawashita Y, Satake N, Morita K. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18 [Suppl 3] iii: 90-93